Zurich, Switzerland - 18 January 2013
Nobel Biocare Board of Directors nominates Franz Maier to join the Board and
concurrently receives a shareholder proposal
Nobel Biocare announced today that its Board of Directors will propose that
Franz Maier be elected as a Member of the Board at the next Annual General
Meeting on 28 March 2013.
To drive the implementation of Nobel Biocare's strategy, one of the priorities
of the Board of Directors has been to broaden and strengthen its operational
and management expertise, in particular in the area of medical technology and
implant-based tooth restoration.
Franz Maier brings a successful track record of over 20 years in both
functional and general management positions, most recently as an Executive
Vice President Sales and Member of the Executive Board of Straumann in the
medical devices and biotechnology industry. From 2007 until the end of 2012,
he also served as a core committee member of the International Team for
Implantology (ITI). Since 2012, Franz Maier has been the Founder and Principal
of Summit Sherpas, a Board, CEO and Private Equity Advisory firm.
Rolf Watter, Chairman of Nobel Biocare: "The Board of Directors is pleased to
propose that Franz Maier joins the Board. Mr. Maier possesses profound
knowledge of our industry. With his excellent understanding of the business
and his proven leadership in developing a sales organization that performed
above market, he will be an ideal addition to help drive the execution of
Nobel Biocare's strategy - helping customers to treat more patients better."
Concurrently to this nomination the Board of Directors received a proposal
from one of its shareholders, Oskar K. Ronner (private investor, 68), for the
election of three new board members at the next Annual General Meeting. Mr.
Ronner proposes Cheryl Benini-Leland (Senior Vice President Siemens Schweiz AG
Building Technologies Division), Rolf Renz (Chief Financial Officer &
Executive Vice President Siemens Southwest Europe, 57) and himself to be
elected by the Annual General Meeting.
The Nomination and Compensation Committee will interview these candidates and
the Board of Directors will publish its recommendation in due course.
About Franz Maier
Mr. Maier (48, German native) joined Swiss med-tech company Straumann in July
2007 as an Executive Vice President Sales and Member of the Executive Board.
Until his departure at the end of 2011, Mr. Maier made a significant
contribution in developing the group to its current leading position in
implant, regenerative and restorative dentistry. Prior to Straumann, Franz
Maier worked for the Wella Group (since 2003 part of Procter & Gamble) for 14
years and held various managerial positions of increasing responsibility in
Product Management, Strategic Management and Sales. He holds a Master of
Science in Business Administration from Passau University in Germany.
For further information, please contact:
VP Investor and Corporate Relations
Tel.: +41 43 211 42 30, +41 79 430 81 46
This media release contains forward-looking statements based on beliefs of
Nobel Biocare's management. When used in this media release, words such as
"anticipate", "believe", "estimate", "expect", "intend", "plan" and "project"
are intended to identify forward-looking statements. They may involve risks
and uncertainties, including technological advances in the medical field,
product demand and market acceptance, the effect of economic conditions, the
impact of competitive products and pricing, foreign currency exchange rates
and other risks. These forward-looking statements reflect the views of Nobel
Biocare as of the date made with respect to future events and are subject to
risks and uncertainties. All of these forward-looking statements are based on
estimates and assumptions made by management of the company and are believed
to be reasonable, though are inherently uncertain and difficult to predict.
Actual results or experience could differ materially from the forward-looking
statements. Nobel Biocare disclaims any intention or obligation to update
these forward-looking statements.
Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative
restorative and esthetic dental solutions. As a complete solutions provider,
Nobel Biocare offers the most comprehensive range of solutions from tooth to
root, for single tooth to fully edentulous indications. The solutions
portfolio covers dental implants (including the key brands NobelActiveTM,
Brånemark System® and NobelReplace®, individualized prosthetics and equipment
(NobelProceraTM guided surgery solutions and biomaterials). Nobel Biocare has
approximately 2'500 employees and recorded revenue of EUR 569.2 million in
2011. The company is headquartered in Zurich, Switzerland. Production takes
place at seven sites located in Canada, Israel, Japan, Sweden, and the US.
Nobel Biocare has 34 direct sales organizations.
Media release (PDF)
Provider Channel Contact
Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries
www.tensid.ch www.newsbox.ch firstname.lastname@example.org
+41 41 763 00 50
Press spacebar to pause and continue. Press esc to stop.